VIA
XENE icon

Vident Investment Advisory’s Xenon Pharmaceuticals XENE Stock Holding History

Vident Investment Advisory’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,731
Closed -$218K – 1247
2021
Q2 		$218K Buy
+11,731
New +$216K 0.01% 1021

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vident Investment Advisory's XENE Position: Q3 2021 in Review

Vident Investment Advisory sold out of Xenon Pharmaceuticals (XENE) in Q3 2021, closing a stake of 11,731 shares — an estimated $218K sold.

Vident Investment Advisory first reported a position in XENE in Q2 2021 and held it in 1 quarter. The position peaked at $218K in Q2 2021. 118 funds tracked by Wall St. Rank hold XENE as of Q3 2021.

  • Vident Investment Advisory reported no remaining Xenon Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 11,731 Xenon Pharmaceuticals shares in Q3 2021, an estimated $218K.
  • Vident Investment Advisory first reported a position in Xenon Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Vident Investment Advisory's Xenon Pharmaceuticals position peaked at $218K in Q2 2021.
  • 118 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.